Endo International PLC (ENDP) Stock Rating Reaffirmed by Citigroup Inc.
Endo International PLC (NASDAQ:ENDP)‘s stock had its “neutral” rating reissued by equities research analysts at Citigroup Inc. in a research note issued to investors on Thursday. They presently have a $11.00 price target on the stock, down from their previous price target of $14.00. Citigroup Inc.’s target price indicates a potential upside of 38.54% from the company’s current price.
A number of other research firms have also weighed in on ENDP. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a report on Tuesday, May 2nd. ValuEngine lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a report on Tuesday. Deutsche Bank AG reduced their target price on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, July 7th. Finally, BMO Capital Markets reissued a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a report on Wednesday, May 17th. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the stock. Endo International PLC has an average rating of “Hold” and an average price target of $15.52.
Endo International PLC (NASDAQ:ENDP) opened at 7.94 on Thursday. The firm has a 50-day moving average of $11.15 and a 200-day moving average of $11.62. Endo International PLC has a 52 week low of $7.81 and a 52 week high of $24.93. The company’s market capitalization is $1.77 billion.
Endo International PLC (NASDAQ:ENDP) last posted its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same period in the previous year, the firm posted $0.86 EPS. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities analysts expect that Endo International PLC will post $3.53 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/10/endo-international-plc-endp-stock-rating-reaffirmed-by-citigroup-inc.html.
A number of hedge funds and other institutional investors have recently modified their holdings of ENDP. First Quadrant L P CA bought a new position in shares of Endo International PLC during the first quarter valued at about $24,556,000. OppenheimerFunds Inc. raised its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Diamond Hill Capital Management Inc. bought a new position in shares of Endo International PLC during the second quarter valued at about $5,454,000. Finally, Ameriprise Financial Inc. raised its position in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares in the last quarter. 93.00% of the stock is currently owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.